Mathias Rosenfeldt Byriel
Mathias Rosenfeldt Byriel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Søren Rafael Rafaelsen
University of Southern Denmark
4 shared publications - Jan Lindebjerg
Danish Colorectal Cancer Center South, Vejle Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark
2 shared publications - Lars Henrik Jensen
Department of Oncology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark
2 shared publications - Signe Timm
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
2 shared publications - Torben Hansen
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
2 shared publications Claus Dam
University of Southern Denmark
1 shared publication
Latest Publications
- 4 June 2026
- Published by SAGE Publications in Acta Radiologica
- Vol. 67 (7) , 601-606
Assessment of intra- and inter-observer variability in T1 relaxation time measurement for rectal cancer
Background: In search of more accurate methods for rectal cancer diagnostics, T1 relaxation time measurement might have potential to become highly clinically relevant. The reproducibility of the methods has only been tested in few studies. Purpose: To investigate the reproducibility of measuring T1 relaxation time in rectal cancer by assessing the intra- and inter-observer variability. Material and Methods: In this inter- and intra-observer study, magnetic resonance imaging (MRI) T1 maps were prospectively collected and analyzed by two observers. All images were obtained on 1.5-T MRI-units. T1 relaxation time was measured by contouring around the tumor border using free hand technique on a single slice. Intra- and inter-observer agreement were evaluated by the intraclass correlation coefficient (ICC) and Bland–Altman plots. Results: A total of 41 MRI scans were included between 1 January and 31 October 2024. The cohort comprised 26 men and 15 women, with a mean age of 70 years (range = 28–92 years). The inter-observer agreement of T1 relaxation time was excellent across two reads with an ICC of 0.93 (95% confidence interval [CI]=0.85–0.97) and 0.91 (95% CI=0.83–0.95). The intra-observer agreement was excellent for both readers with an ICC of 0.94 (95% CI=0.88–0.97) for the less experienced reader and 0.90 (95% CI=0.81–0.95) for the experienced reader. Conclusion: In conclusion, analysis of MRI T1 maps and measuring of T1 relaxation time for evaluation of rectal cancer is has a high ICC. A reliable method is essential in the evaluation of complete response after neoadjuvant treatment.
- 4 June 2026
- Published by SAGE Publications in Acta Radiologica
- Vol. 67 (7) , 601-606
Assessment of intra- and inter-observer variability in T1 relaxation time measurement for rectal cancer
Background: In search of more accurate methods for rectal cancer diagnostics, T1 relaxation time measurement might have potential to become highly clinically relevant. The reproducibility of the methods has only been tested in few studies. Purpose: To investigate the reproducibility of measuring T1 relaxation time in rectal cancer by assessing the intra- and inter-observer variability. Material and Methods: In this inter- and intra-observer study, magnetic resonance imaging (MRI) T1 maps were prospectively collected and analyzed by two observers. All images were obtained on 1.5-T MRI-units. T1 relaxation time was measured by contouring around the tumor border using free hand technique on a single slice. Intra- and inter-observer agreement were evaluated by the intraclass correlation coefficient (ICC) and Bland–Altman plots. Results: A total of 41 MRI scans were included between 1 January and 31 October 2024. The cohort comprised 26 men and 15 women, with a mean age of 70 years (range = 28–92 years). The inter-observer agreement of T1 relaxation time was excellent across two reads with an ICC of 0.93 (95% confidence interval [CI]=0.85–0.97) and 0.91 (95% CI=0.83–0.95). The intra-observer agreement was excellent for both readers with an ICC of 0.94 (95% CI=0.88–0.97) for the less experienced reader and 0.90 (95% CI=0.81–0.95) for the experienced reader. Conclusion: In conclusion, analysis of MRI T1 maps and measuring of T1 relaxation time for evaluation of rectal cancer is has a high ICC. A reliable method is essential in the evaluation of complete response after neoadjuvant treatment.
- Open Access
- 24 April 2026
- Published by Elsevier in SSRN Electronic Journal
Quantitative MRI T1 Relaxation Time as a Biomarker of Complete Response in Rectal Cancer Six Weeks after Neoadjuvant Therapy: A Prospective Study
Purpose The purpose of the study was to investigate the performance of quantitative magnetic resonance imaging (MRI) T1 relaxation time for early identification of complete response (CR) following neoadjuvant therapy in patients with rectal cancer. Materials and methods We prospectively included patients with rectal cancer selected for neoadjuvant therapy. We used a 1.5 T MRI unit. T1 relaxation time was measured at baseline and six weeks after completion of neoadjuvant therapy. Endpoints were pathological CR confirmed by the surgical specimen in operated cases or clinical CR determined by three-month follow-up MRI combined with endoscopy in non-operated (watch-and-wait) cases. Data were analysed using paired t-test. Results We included 44 patients (27 male, mean age 63 years (36 – 83)). At baseline, patients with and without CR had similar T1 relaxation times with means of 1370 ms (95% CI 1294 – 1446 ms) for the CR-group and 1419 ms (95% CI: 1365 – 1473 ms) for the incomplete response (iCR)-group, p=0.22. At six weeks follow-up, the CR-group decreased to 632 ms (95% CI 542 – 723) and the iCR-group remained at 1301 ms (95% CI 1165 – 1437). We found a cut-off value of 1088 ms with a sensitivity at 88.5%, specificity at 100% and an area under the curve of 0.94 (95% CI: 0.82 – 1.00). Positive predictive value for CR was 100% and the negative predictive value 85.7%. Conclusion Quantitative MRI T1 relaxation time shows a strong performance for identification of CR six weeks after neoadjuvant therapy in rectal cancer and may support response-adapted treatment strategies.
- 24 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessQuantitative MRI T1 Relaxation Time as a Biomarker of Complete Response in Rectal Cancer Six Weeks after Neoadjuvant Therapy: A Prospective Study
Purpose The purpose of the study was to investigate the performance of quantitative magnetic resonance imaging (MRI) T1 relaxation time for early identification of complete response (CR) following neoadjuvant therapy in patients with rectal cancer. Materials and methods We prospectively included patients with rectal cancer selected for neoadjuvant therapy. We used a 1.5 T MRI unit. T1 relaxation time was measured at baseline and six weeks after completion of neoadjuvant therapy. Endpoints were pathological CR confirmed by the surgical specimen in operated cases or clinical CR determined by three-month follow-up MRI combined with endoscopy in non-operated (watch-and-wait) cases. Data were analysed using paired t-test. Results We included 44 patients (27 male, mean age 63 years (36 – 83)). At baseline, patients with and without CR had similar T1 relaxation times with means of 1370 ms (95% CI 1294 – 1446 ms) for the CR-group and 1419 ms (95% CI: 1365 – 1473 ms) for the incomplete response (iCR)-group, p=0.22. At six weeks follow-up, the CR-group decreased to 632 ms (95% CI 542 – 723) and the iCR-group remained at 1301 ms (95% CI 1165 – 1437). We found a cut-off value of 1088 ms with a sensitivity at 88.5%, specificity at 100% and an area under the curve of 0.94 (95% CI: 0.82 – 1.00). Positive predictive value for CR was 100% and the negative predictive value 85.7%. Conclusion Quantitative MRI T1 relaxation time shows a strong performance for identification of CR six weeks after neoadjuvant therapy in rectal cancer and may support response-adapted treatment strategies.
- 9 March 2026
- Published by SAGE Publications in Acta Radiologica
- Vol. 67 (5) , 418-425
Inter-observer variability for detection of suspected ileocolonic Crohn’s disease with magnetic resonance enterography
Background: Magnetic resonance enterography (MRE) can visualize Crohn's disease (CD) and its complications. Purpose: To determine the inter-observer agreement for the detection of ileocolonic CD. Material and Methods: This post-hoc analysis included MRE scans from 48 patients selected from a prospective, blinded multicenter study of patients with suspected CD. Based on ileocolonoscopy in the main study, CD was diagnosed in 39 (81%) patients, with colonic involvement in 36 (69%). Two senior radiologists and two junior doctors undergoing specialist training, blinded to clinical data assessed the image quality, CD presence, and disease severity. Results: The inter-observer agreement for CD detection varied by location: terminal ileum (κ = 0.77, 95% confidence interval [CI] = 0.63–0.89), colon (κ = 0.59, 95% CI = 0.42–0.74), and ileocolon (κ = 0.65, 95% CI = 0.49–0.80). Agreement was higher among senior radiologists than juniors: terminal ileum (κ = 0.83 vs. 0.73; P = 0.60) and colon (κ = 0.73 vs. 0.41; P = 0.11), though differences were not statistically significant. The inter-observer agreement for disease severity was poor to moderate with intraclass correlation coefficients (ICCs) of 0.51 (95% CI = 0.35–0.67) for the MaRIA and 0.46 (95% CI = 0.29–0.62) for the simplified MaRIA. Senior radiologists showed higher consistency, with moderate to good agreement: ICC of 0.69 for the MaRIA, 0.70 for the simplified MaRIA, and 0.80 for bowel wall thickness. Conclusion: In early CD, MRE demonstrated moderate to substantial inter-observer agreement for ileocolonic evaluation. Limitations in colonic assessment likely reflect early disease detection rather than observer variability, highlighting the need for a complementary assessment.
- 9 March 2026
- Published by SAGE Publications in Acta Radiologica
- Vol. 67 (5) , 418-425
Inter-observer variability for detection of suspected ileocolonic Crohn’s disease with magnetic resonance enterography
Background: Magnetic resonance enterography (MRE) can visualize Crohn's disease (CD) and its complications. Purpose: To determine the inter-observer agreement for the detection of ileocolonic CD. Material and Methods: This post-hoc analysis included MRE scans from 48 patients selected from a prospective, blinded multicenter study of patients with suspected CD. Based on ileocolonoscopy in the main study, CD was diagnosed in 39 (81%) patients, with colonic involvement in 36 (69%). Two senior radiologists and two junior doctors undergoing specialist training, blinded to clinical data assessed the image quality, CD presence, and disease severity. Results: The inter-observer agreement for CD detection varied by location: terminal ileum (κ = 0.77, 95% confidence interval [CI] = 0.63–0.89), colon (κ = 0.59, 95% CI = 0.42–0.74), and ileocolon (κ = 0.65, 95% CI = 0.49–0.80). Agreement was higher among senior radiologists than juniors: terminal ileum (κ = 0.83 vs. 0.73; P = 0.60) and colon (κ = 0.73 vs. 0.41; P = 0.11), though differences were not statistically significant. The inter-observer agreement for disease severity was poor to moderate with intraclass correlation coefficients (ICCs) of 0.51 (95% CI = 0.35–0.67) for the MaRIA and 0.46 (95% CI = 0.29–0.62) for the simplified MaRIA. Senior radiologists showed higher consistency, with moderate to good agreement: ICC of 0.69 for the MaRIA, 0.70 for the simplified MaRIA, and 0.80 for bowel wall thickness. Conclusion: In early CD, MRE demonstrated moderate to substantial inter-observer agreement for ileocolonic evaluation. Limitations in colonic assessment likely reflect early disease detection rather than observer variability, highlighting the need for a complementary assessment.
- Open Access
- 30 July 2025
- Published by SAGE Publications in Acta Radiologica Open
- Vol. 14 (7)
MRI T1 relaxation time for evaluating early complete response to neoadjuvant treatment in rectal cancer: measurement at six weeks – a protocol article
Background: Management of rectal cancer requires accurate staging and treatment. Neoadjuvant chemoradiotherapy offers tumour size reduction and mitigation of the risk of local relapse. Patients with complete response to neoadjuvant treatment can be enclosed in watchful waiting (WW). Recent studies have explored magnetic resonance imaging (MRI) T1 relaxation time (T1RT) as a predictive biomarker for treatment response in rectal cancer. Preliminary findings indicate that lower T1RT correlates with pathologic complete response. However, inclusion of patients in WW remains unexplored. Purpose: This prospective study aims to investigate T1RT 6 weeks after neoadjuvant treatment and the ability to determine complete response. Material and methods: MRI scans are conducted on a 1.5 T MRI-unit. T1RT is measured at time of diagnosis and 6 weeks after neoadjuvant treatment. Experienced radiologists analyse T1RT using specialised software. Treatment decisions are made in multidisciplinary team conferences based on tumour staging. Endpoints include tumour visibility on MRI and endoscopy, along with histopathological analysis of surgical specimens. Statistical methods include t test and receiver operating characteristic curves. Sample size calculations showed we must enrol 76 participants to achieve a statistical power of 80% with an α = 0.05. Results: Data analysis begins in winter 2025. Results are planned to be submitted in spring 2026. Conclusion: The implications of this study extend to the potential refinement of treatment strategies, offering patients the prospect of improved outcomes and the potential avoidance of surgery-associated risks. We expect to find a lower relaxation time in fibrotic tissue compared to non-responsive cancerous tissue after 6 weeks.
- 30 July 2025
- Published by SAGE Publications in Acta Radiologica Open
- Vol. 14 (7)
Open AccessMRI T1 relaxation time for evaluating early complete response to neoadjuvant treatment in rectal cancer: measurement at six weeks – a protocol article
Background: Management of rectal cancer requires accurate staging and treatment. Neoadjuvant chemoradiotherapy offers tumour size reduction and mitigation of the risk of local relapse. Patients with complete response to neoadjuvant treatment can be enclosed in watchful waiting (WW). Recent studies have explored magnetic resonance imaging (MRI) T1 relaxation time (T1RT) as a predictive biomarker for treatment response in rectal cancer. Preliminary findings indicate that lower T1RT correlates with pathologic complete response. However, inclusion of patients in WW remains unexplored. Purpose: This prospective study aims to investigate T1RT 6 weeks after neoadjuvant treatment and the ability to determine complete response. Material and methods: MRI scans are conducted on a 1.5 T MRI-unit. T1RT is measured at time of diagnosis and 6 weeks after neoadjuvant treatment. Experienced radiologists analyse T1RT using specialised software. Treatment decisions are made in multidisciplinary team conferences based on tumour staging. Endpoints include tumour visibility on MRI and endoscopy, along with histopathological analysis of surgical specimens. Statistical methods include t test and receiver operating characteristic curves. Sample size calculations showed we must enrol 76 participants to achieve a statistical power of 80% with an α = 0.05. Results: Data analysis begins in winter 2025. Results are planned to be submitted in spring 2026. Conclusion: The implications of this study extend to the potential refinement of treatment strategies, offering patients the prospect of improved outcomes and the potential avoidance of surgery-associated risks. We expect to find a lower relaxation time in fibrotic tissue compared to non-responsive cancerous tissue after 6 weeks.